ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1

Targeted therapy using monoclonal antibodies conjugated to toxins is gaining space in the treatment of cancer. Here, we report the anti-tumor effect of a new antibody drug conjugate (ADC) delivering a HDAC inhibitor to ErbB2+ solid tumors. Trastuzumab was partially reduced with tris [2-carboxyethyl]...

Descripción completa

Detalles Bibliográficos
Autores principales: Milazzo, Ferdinando Maria, Vesci, Loredana, Anastasi, Anna Maria, Chiapparino, Caterina, Rosi, Antonio, Giannini, Giuseppe, Taddei, Maurizio, Cini, Elena, Faltoni, Valentina, Petricci, Elena, Battistuzzi, Gianfranco, Salvini, Laura, Carollo, Valeria, De Santis, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989603/
https://www.ncbi.nlm.nih.gov/pubmed/32039017
http://dx.doi.org/10.3389/fonc.2019.01534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989603/
https://www.ncbi.nlm.nih.gov/pubmed/32039017
http://dx.doi.org/10.3389/fonc.2019.01534

Ejemplares similares